View in EDS HTML Full Text PDF Full Text

Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia.

Saved in:
Bibliographic Details
Title: Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia.
Authors: Xia D; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Lianoglou S; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Sandmann T; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Calvert M; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Suh JH; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Thomsen E; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Dugas J; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Pizzo ME; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., DeVos SL; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Earr TK; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Lin CC; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Davis S; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Ha C; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Leung AW; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Nguyen H; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Chau R; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Yulyaningsih E; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Lopez I; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Solanoy H; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Masoud ST; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Liang CC; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Lin K; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Astarita G; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Khoury N; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Zuchero JY; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Thorne RG; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA.; Department of Pharmaceutics, University of Minnesota, 9-177 Weaver-Densford Hall, 308 Harvard St. SE, Minneapolis, MN, 55455, USA., Shen K; Gladstone Institute of Neurological Disease, San Francisco, CA, 94158, USA.; Department of Neurology, University of California, San Francisco, CA, 94158, USA., Miller S; Gladstone Institute of Neurological Disease, San Francisco, CA, 94158, USA.; Department of Neurology, University of California, San Francisco, CA, 94158, USA., Palop JJ; Gladstone Institute of Neurological Disease, San Francisco, CA, 94158, USA.; Department of Neurology, University of California, San Francisco, CA, 94158, USA., Garceau D; The Jackson Lab, Bar Harbor, Maine, USA., Sasner M; The Jackson Lab, Bar Harbor, Maine, USA., Whitesell JD; Allen Institute for Brain Science, Seattle, Washington, USA., Harris JA; Allen Institute for Brain Science, Seattle, Washington, USA., Hummel S; German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Gnörich J; German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Wind K; German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Kunze L; German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Zatcepin A; German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Brendel M; German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Willem M; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Haass C; German Center for Neurodegenerative Diseases (DZNE) Munich, 81377, Munich, Germany.; Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, Ludwig- Maximilians-Universität, München, 81377, Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), 81377, Munich, Germany., Barnett D; Appel Alzheimer's Disease Research Institute, Weill Cornell Medicine, New York, NY, USA.; Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.; Neuroscience Graduate Program, Weill Cornell Medicine, New York, NY, USA., Zimmer TS; Appel Alzheimer's Disease Research Institute, Weill Cornell Medicine, New York, NY, USA.; Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA., Orr AG; Appel Alzheimer's Disease Research Institute, Weill Cornell Medicine, New York, NY, USA.; Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.; Neuroscience Graduate Program, Weill Cornell Medicine, New York, NY, USA., Scearce-Levie K; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Lewcock JW; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Di Paolo G; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA., Sanchez PE; Denali Therapeutics, Inc., 161 Oyster Point Blvd, South San Francisco, California, 94080, USA. sanchez@dnli.com.
Source: Molecular neurodegeneration [Mol Neurodegener] 2022 Jun 11; Vol. 17 (1), pp. 41. Date of Electronic Publication: 2022 Jun 11.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101266600 Publication Model: Electronic Cited Medium: Internet ISSN: 1750-1326 (Electronic) Linking ISSN: 17501326 NLM ISO Abbreviation: Mol Neurodegener Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1750-1326
DOI:10.1186/s13024-022-00547-7